Drug Profile
Research programme: guanylate cyclase C agonists - Synergy Pharmaceuticals
Alternative Names: GC-C receptor agonists - SynergyLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Synergy Pharmaceuticals Inc
- Class Peptide hormones; Peptides
- Mechanism of Action Enterotoxin receptor agonists; Sodium-bile acid cotransporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Hypercholesterolaemia; Inflammatory bowel diseases; Ulcerative colitis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hypercholesterolaemia in USA (PO)
- 25 Oct 2012 No development reported - Preclinical for Inflammatory bowel disease in USA (PO)
- 25 Oct 2012 No development reported - Preclinical for Ulcerative colitis in USA (PO)